Last reviewed · How we verify

NCT04962386

Clinical Efficacy of Hormone Replacement Therapy in Treating Perimenopausal Women With MGD

Status unknown Last updated 13 September 2021
What this trial tests

trial testing Hormone replacement therapy in Meibomian Gland Dysfunction in 30 participants. Status unknown.

Timeline
6 March 2019
Primary endpoint
6 March 2022
6 March 2022

Quick facts

Lead sponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment30
Start date6 March 2019
Primary completion6 March 2022
Estimated completion6 March 2022
Sites2 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

Adults 25 to 45, female only, with Meibomian Gland Dysfunction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This project aims to evaluate the possible relationship between MGD and HRT in perimenopausal women

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Hormone replacement therapy

Trials testing the same drug.

Other recruiting trials for Meibomian Gland Dysfunction

Currently open trials in the same condition.

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04962386.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing